ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0773

Anti-Citrullinated Histone Antibody CIT-013 Targets NETs in Inflamed Joints and Halts NET-mediated Joint Deterioration
Abstract Number: 0064

Anti-Citrullinated Protein Antibodies Arise During Affinity Maturation of Germline-Encoded Antibodies to Carbamylated Proteins in Rheumatoid Arthritis
Abstract Number: 0098

Anti-HSP90α as a Protective Natural Antibody Against Secondary Antiphospholipid Syndrome in Systemic Lupus Erythematosus
Abstract Number: 2305

Anti-Ku Positivity in Primary Sjögren’s Disease Is Associated with a More Systemic Active Disease
Abstract Number: 0338

Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
Abstract Number: 2667

Anti-Mi2 Autoantibodies in Dermatomyositis Patients Also Recognize Autoimmune Regulator (AIRE) Protein
Abstract Number: 1266

Anti-Mitochondrial Antibodies Associate with Disease Activity and IFNα Expression in Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 0713

Anti-muscarinic 3 Antibodies in SSc Associate with a More Significant GI and Extraintestinal Clinical Phenotype
Abstract Number: 0642

Anti-Myxovirus Resistance Protein 1: A Novel Biomarker for Autoimmune Myositis and Interstitial Lung Disease in Systemic Lupus Erythematosus
Abstract Number: 1610

Anti-neutrophil Cytoplasmic Antibodies Associated Interstitial Pneumonia: A New Clinical Entity?
Abstract Number: 2232

Anti-RA33 Autoantibodies Are Unique, Sensitive Biomarkers for the Identification of Seronegative Rheumatoid Arthritis in a U.S. Cohort
Abstract Number: 2390

Anti-Sm Antibody Titers Vary During SLE Disease Course
Abstract Number: 0241

Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Abstract Number: 1888

Anti-Spike Antibodies Protect Against COVID-19 Infection in Immune-Mediated Inflammatory Diseases: Findings from the SUCCEED Study
Abstract Number: 1159

Anti-synthetase Syndrome (ASSD) Related Interstitial Lung Disease (ILD) in Comparison to Non-ASSD Related ILDs: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].